Highest-materiality recent filing
MannKind Q2 2026 revenue $109.4M (+43% YoY); Afrezza pediatric and Furoscix ReadyFlow approved
Q2 total revenue $109.4M, up 43% YoY; Furoscix contributed $22.2M in net sales.
MannKind gets FDA approval for Furoscix ReadyFlow; raises $50M in private placement
FDA approved Furoscix ReadyFlow (furosemide injection) for edema in adults with heart failure or chronic kidney disease.
FDA approves Afrezza for pediatric diabetes patients ages 6+
FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29
FDA informed MannKind on May 27, 2026 it is released from postmarketing requirement to assess pulmonary malignancy risk in 8,000-10,000 patients.
MannKind Q1 total revenue $90.2M (+15% YoY); Furoscix adds $15.5M; cash $134M
Total revenue $90.2M (+15% YoY); royalties from Tyvaso DPI up 9% to $32.7M.
MannKind Q4 revenue $112M (+46% YoY); Furoscix adds $23M in first quarter
Total revenues $112M in Q4 2025, up 46% vs Q4 2024; full-year revenues $349M, up 22%.
MannKind pro forma shows $36.1M net loss for H1 2025 post-scPharma acquisition
Acquired scPharma for $5.35/share cash plus CVR (up to $1.00/share); total consideration $396.4M cash.
MannKind discontinues Phase 3 MNKD-101 trial for NTM lung disease after futility analysis
Discontinuation based on interim analysis of first 46 participants; none showed sputum culture conversion.
MannKind Q3 revenue $82.1M (+17% YoY); completes scPharma acquisition
Q3 2025 revenues $82.1M (+17% YoY); YTD revenues $237.0M (+14%).
MannKind completes $296.5M acquisition of scPharmaceuticals; funds with $250M debt
Tender offer expired Oct 6 with 73.47% shares tendered; merger closed Oct 7, 2025; scPharma becomes wholly owned subsidiary.
MannKind receives $5M upfront from United Therapeutics for new product option exercise
MannKind entered First Amendment with United Therapeutics to exercise option for an additional development product using its Technosphere platform.
MannKind to acquire scPharmaceuticals for $5.35/share plus CVR up to $1.00/share
Offer price: $5.35 cash + one contingent value right (CVR) per share; CVR milestones up to $1.00 aggregate.
MannKind Q2 revenue $76.5M (+6% YoY); Afrezza sBLA for pediatric population submitted
Total revenues $76.5M, up 6% YoY; net income $0.7M versus net loss $2.0M in Q2 2024.
MannKind Q1 revenue $78M (+18% YoY); net income $13.2M (+24%)
1Q25 revenue $78.4M (+18% YoY); GAAP net income $13.2M (+24%); non-GAAP net income $21.6M (+43%).
MannKind reports 2024 revenue of $286M, net income of $28M; debt reduced by $236M
Full year 2024 revenue $286M (+43% YoY); Q4 revenue $77M (+31% YoY).
MannKind exchanges $193.7M of 2.50% convertible notes for 26.7M shares plus $89.2M cash
Aggregate principal $193.7M of 2.50% Convertible Senior Notes due 2026 exchanged for 26,749,559 shares of common stock.
MannKind Q3 total revenue $70M (+37% YoY); YTD net income $20M, non-GAAP $45M
Q3 total revenue $70.1M (+37% YoY); YTD revenue $208.7M (+49% YoY); YTD net income $20M.
MannKind Q2 revenue $72M (+49% YoY), net income $9M YTD; pipeline advances
Q2 total revenues $72.4M, up 49% vs. $48.6M in Q2 2023; YTD revenues $138.6M, up 55%.
MannKind Q1 revenue $66M (+63% YoY); net income $11M; FDA Fast Track for MNKD-101
Total revenues $66.3M (+63% YoY); GAAP net income $11M; non-GAAP net income $15M.
MannKind repays ~$31.6M MidCap debt, terminates $8.9M convertible note with Mann Group
On Apr 1, 2024, repaid ~$31.6M under MidCap Loan Agreement (incl. $2.8M exit fee, $0.3M prepayment fee); all liens released.
MannKind FY 2023 revenue doubled to $199M; Q4 posts GAAP net income of $1M
FY 2023 total revenues $199M, +99% YoY; Q4 revenues $58M, +62% YoY.
MannKind sells 1% Tyvaso DPI royalty to Sagard for $150M upfront, retains 9%
Sagard pays MannKind $150M upfront for a 1% royalty on global net sales of Tyvaso DPI through Dec 31, 2042.
MannKind restructures Amphastar supply deal: lowers annual commitments, adds capacity fees
Prior total purchase commitments of €58.7M for 2024-27 replaced; new commitments for 2024 = €2.9M, 2025 = €1.5M.
MannKind Q3 total revenue $51M, up 56% YoY; net income $2M GAAP
Total revenue $51.3M, +56% YoY; net income $2M (GAAP); non-GAAP net income $4M.
MannKind Q2 total revenues $49M (+157% YoY); Tyvaso DPI royalties $19M (+63% QoQ)
Tyvaso DPI royalties $19M in Q2, up 63% from Q1, driven by strong patient demand.
MannKind: fire at contract manufacturer delays MNKD-101 clinical supply by 3-6 months
Fire at contract manufacturer's German facility producing clofazimine inhalation solution (MNKD-101).
MannKind Q1 2023 revenues jump 239% to $41M; loss from ops down 72%
Total revenues $40.6M, +239% vs Q1 2022; Tyvaso DPI contributed $23M (services + royalties).
MannKind Q1 2023 total revenues $40.6M (+239% YoY); Tyvaso DPI drives $23M
Total revenues $40.6M vs $12.0M in Q1 2022, a 239% increase.
MannKind reports 2022 total revenues of $100M, up 32% YoY; Tyvaso DPI royalties $16M
Q4 2022 total revenues $36.1M (+188% YoY); full-year $99.8M (+32% vs 2021).
MannKind Q3 2022 revenue $32.8M, up 48% YoY; net loss widens to $14.4M
Total revenues $32.8M (+48% YoY); Afrezza net revenue $10.8M (+11%), V-Go net revenue $5.4M.
MannKind Q2 2022 revenue $18.9M, net loss narrows to $29.0M; Tyvaso DPI approved
Commercial product net revenue $12.7M (Afrezza $10.6M, V-Go $2.1M), up 28% YoY; collaboration $5.9M.
FDA approves Tyvaso DPI using MannKind's Technosphere platform; availability June 2022
Tyvaso DPI is second FDA-approved product using MannKind's Technosphere inhalation platform; first dry powder inhaled treatment for PAH and PH-ILD.
Purchase price: $10.0M plus book value of finished goods inventory (not to exceed $7.0M) and up to $10.0M in sales-based milestone payments.
MannKind Q1: Afrezza net revenue $9.8M (+21% YoY); net loss $26.0M; cash $233M
Afrezza net revenue $9.8M, up 21% vs Q1 2021; gross margin improved to 77% from 47%.
MannKind reports 2021 revenue $75.4M, +16%; Afrezza Q4 record $11.3M; net loss widens
Total revenues 2021: $75.4M (+16% vs 2020); Afrezza net revenue $39.2M (+21% YoY)
MannKind partner UT's Tyvaso DPI NDA accepted for FDA Class 1 review; goal Feb 2022
FDA accepted United Therapeutics' resubmitted NDA for Tyvaso DPI as a Class 1 response.
United Therapeutics resubmits Tyvaso DPI NDA to FDA after CRL
UT received a Complete Response Letter from FDA on Oct 18, 2021 for Tyvaso DPI.
On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.
the board of directors of the Company appointed Ms. Sabella as Executive Vice President, Operations, effective January 6, 2025.
On January 2, 2025, Lauren Sabella notified us of her intention to retire from MannKind Corporation (the “Company”), effective July 18, 2025
His employment will end concurrently with his appointment to the Board on the Effective Date.
On August 13, 2024, the Board approved the appointment of Steven B. Binder to the Board, effective on the Effective Date.
On August 13, 2024, Kent Kresa notified us of his decision to retire from our Board of Directors (the “Board”), effective September 30, 2024 (the “Effective Date”).
On March 25, 2024, the Company’s board of directors appointed Christopher Prentiss as the Company’s Chief Financial Officer and principal accounting officer, effective on April 22, 2024, succeeding Mr. Binder in these capacities.
Effective April 22, 2024 (the “Effective Date”), Steven B. Binder is retiring as the Chief Financial Officer and principal accounting officer of MannKind Corporation (the “Company”).
On March 21, 2023, Lauren M. Sabella was appointed by the board of directors of MannKind Corporation (the “Company”) as Executive Vice President, Chief Operating Officer of the Company, with such appointment to be effective on March 27, 2023.
On October 26, 2022, MannKind Corporation (the “Company”) and Joseph Kocinsky, the Company’s Chief Technology Officer, discussed and agreed that Mr. Kocinsky’s duties and responsibilities will be reduced such that he will no longer function in the same position, effective October 31, 2022 (the “Effective Date”).
Max materiality 0.90 · Median 0.70 · Most common event earnings